Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis Distler JH; Distler ORheumatology (Oxford) 2008[Oct]; 47 Suppl 5 (ä): v10-1Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF receptor or Src kinases might be promising targets for anti-fibrotic approaches. Dual inhibition of c-Abl and PDGF receptor by imatinib and nilotinib, and inhibition of Src kinases either selectively by SU6656 or in combination with c-Abl and PDGF by dasatinib exerted potent anti-fibrotic effects. Imatinib, nilotinib, dasatinib and SU6656 reduced dose-dependently the synthesis of extracellular matrix protein in human dermal fibroblasts in vitro and prevented fibrosis in the mouse model of bleomycin-induced skin fibrosis. Clinical data from patients with chronic myelogenous leukaemia suggest that imatinib, nilotinib and dasatinib are well tolerated. Based on the promising pre-clinical data, imatinib is currently evaluated in clinical trials for the treatment of fibrosis in SSc and trials with other tyrosine kinase inhibitors are in preparation.|Animals[MESH]|Benzamides[MESH]|Clinical Trials as Topic[MESH]|Dasatinib[MESH]|Fibrosis[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Indoles/therapeutic use[MESH]|Piperazines/*therapeutic use[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Proto-Oncogene Proteins c-abl/*antagonists & inhibitors[MESH]|Pyrimidines/*therapeutic use[MESH]|Scleroderma, Systemic/*drug therapy/enzymology[MESH]|Skin/enzymology[MESH]|Sulfonamides/therapeutic use[MESH]|Thiazoles/therapeutic use[MESH] |
